GIGABYTE
GIGABYTE is exhibiting cutting-edge technologies and solutions at COMPUTEX 2023, presenting the theme “Future of COMPUTING”. From May 30th to June 2nd, GIGABYTE is showcasing over 110 products that are driving future industry transformation, demonstrating the emerging trends of AI technology and sustainability, on the 1st floor, Taipei Nangang Exhibition Center, Hall 1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005657/en/
(Photo: Business Wire)
Win Big with AI through GIGABYTE’s Pioneering GPU/HPC Servers
GIGABYTE and its subsidiary, Giga Computing, are introducing unparalleled AI/HPC server lineups, leading the era of exascale supercomputing. One of the stars is the industry’s first NVIDIA-certified HGX H100 8-GPU SXM5 server, G593-SD0. Equipped with the 4th Gen Intel Xeon Scalable Processors and GIGABYTE’s industry-leading thermal design, G593-SD0 can perform extremely intensive workloads from generative AI and deep learning model training within a density-optimized 5U server chassis, making it a top choice for data centers aimed for AI breakthroughs.
In addition, GIGABYTE is debuting AI computing servers supporting NVIDIA Grace CPU and Grace Hopper Superchips. The high-density servers are accelerated with NVLink-C2C technology under the ARM Neoverse V2 platform, setting a new standard for AI/HPC computing efficiency and bandwidth.
Embrace Sustainability with GIGABYTE’s World-Acclaimed Green Computing Solutions
GIGABYTE’s green computing solutions are elevating the standards of data center energy efficiency to the next level. It is the first time for GIGABYTE to showcase three models of immersion cooling tanks at COMPUTEX, to demonstrate how green computing can eliminate the need for power-hungry fans and air conditioning. The solutions enable customers to therefore meet their sustainability goals while dealing with the surging demand for computing-heavy innovations.
In addition to green computing solutions, GIGABYTE is also highlighting its long-standing efforts in achieving “sustainable productivity” at COMPUTEX for the first time. GIGABYTE has been developing innovative eco-friendly products, optimizing production lines, which have reduced energy consumption by 34% and emissions by 43% since 2009, and practicing circular economy through e-waste repair, recycling, and refurbishment. In 2021 and 2022, GIGABYTE was rated “Leadership-Level” by CDP Climate Assessment for its distinguished sustainability actions and accomplishments.
Advance Data Centers with Next-Generation Server Selections
Technology development and digital services rely heavily on advanced data centers. GIGABYTE is exhibiting a wide range of servers and motherboards suitable for cloud computing, data storage, and edge computing, as well as servers displayed in EIA and OCP (Open Compute Project) standardized racks. The latest GIGABYTE enterprise products support the latest chips from AMD, Ampere, Intel, and NVIDIA, which allow data centers to benefit from optimized performance, flexibility, scalability, and efficiency.
Enable Smart Industry with GIGABYTE’s Superior AI-Driven Deployment
The development of network communication has spurred the rise of the Internet of Things (IoT). At COMPUTEX, GIGABYTE is showcasing how IoT can utilize AI technology to modernize manufacturing, retail, autonomous vehicles, healthcare, and other sectors. The key technology on display includes industrial motherboards, embedded systems, microcomputers, AI image recognition systems, and the Internet of Vehicles, leveraging next-generation chip technology to unlock boundless opportunities through digital transformation.
Reshape the Game with Award-Winning AORUS and AERO Computers
GIGABYTE has always adhered to a design philosophy that delivers outstanding consumer experience. AORUS gaming and AERO creator series have won 15 Red Dot Design Awards in 2023 across motherboards, graphics cards, laptops, large 4K monitors, and gaming peripherals, demonstrating GIGABYTE’s dedicated innovation and aesthetic excellence. In addition to the award-winning AORUS and AERO products, GIGABYTE will also showcase various selections of motherboards, SSD drives, and DIY kits, impressing tech enthusiasts with abundant choices of excellence.
Visit GIGABYTE’s COMPUTEX event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005657/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom